RLMDHIGH SIGNALOPERATIONAL10-K

RLMD terminated its lead drug candidate REL-1017 (esmethadone) in July 2025 following a failed pivotal trial and pivoted to acquiring new development candidates while substantially reducing R&D spending.

The termination of the company's primary drug development program represents a fundamental strategic shift that eliminates years of investment and research focus. While the company claims to be leveraging its development expertise to acquire new candidates, this pivot introduces significant execution risk and uncertainty about the timeline for advancing new therapeutic programs. The dramatic increase in outstanding shares from 33 million to 105 million suggests substantial dilution likely occurred to fund operations during this transition period.

Comparing 2026-03-19 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

RLMD's financials reflect the impact of terminating its primary development program, with R&D expenses declining meaningfully from $46.2M to $26.9M year-over-year. Operating losses narrowed correspondingly from $83.9M to $59.1M, though this improvement stems from reduced spending rather than operational progress. The company maintains a challenging cash burn profile with operating cash flow remaining substantially negative at $45.8M, while current liabilities decreased to $6.4M, suggesting some balance sheet improvement during the strategic transition.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-97.8%
$220K$5K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Gross Profit
P&L
-49%
$2K$1K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

R&D Expense
P&L
-41.8%
$46.2M$26.9M

R&D spending cut 41.8% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-37.5%
$10.3M$6.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Revenue
P&L
-35.4%
$8K$5K

Revenue declined 35.4% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
+29.6%
-$83.9M-$59.1M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+28.3%
-$80.0M-$57.4M

Net income grew 28.3% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-27.2%
$10.3M$7.5M

Liabilities reduced 27.2% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+11.5%
-$51.8M-$45.8M

Operating cash flow grew 11.5% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-27
ADDED
As of March 16, 2026, there were 104,890,223 shares of common stock, $0.001 par value per share, outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 40 7A.
Changes in and Disagreements with Accountants on Accounting, and Financial Disclosure 44 9A.
We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025.
We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates, while terminating further work on esmethadone (d-methadone, dextromethadone or REL-1017).
Following the 2024 REL-1017 setback and subsequent post hoc analyses, the program was terminated effective July 7, 2025.
Currently, our lead product, NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel.
NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of NMIBC.
We intend to develop NDV-01 for two separate indications: (1) the treatment of high-risk, 2nd line Bacillus Calmette-Gu rin (BCG)-unresponsive NMIBC and (2) the treatment of intermediate risk patients in the adjuvant setting.
We expect to initiate Phase 3 programs for each indication mid-2026.
REMOVED
As of March 25, 2025, there were 33,191,622 shares of common stock, $0.001 par value per share, outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 41 7A.
Changes in and Disagreements with Accountants on Accounting, and Financial Disclosure 46 9A.
We substantially redesigned our development programs following a comprehensive strategic review occasioned by disappointing interim analysis results in December 2024 indicating that our then lead development candidate, esmethadone (d-methadone, dextromethadone, or REL-1017) for the adjunctive treatment of Major Depressive Disorder (MDD), was unlikely to succeed in its pivotal trial.
We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates, while pausing further work on REL-1017.
The REL-P11 program has successfully completed a Phase 1 safety study.
However, in light of an ongoing strategic review of this business opportunity, the changing regulatory landscape for psychedelics, its early stage of development and the acquisition of new, more advanced product candidates, this program has also been paused.
REL-1017 Program Updates Since 2013, we had been developing esmethadone as our lead product candidate as an oral agent for the treatment of depression and other potential indications.
In December 2024, we reported that the pre-planned interim analysis, conducted by the Independent Data Monitoring Committee (DMC), of Reliance II, our Phase 3 study of esmethadone as a potential adjunctive treatment for MDD, indicated that the study was futile and unlikely to meet the primary efficacy endpoint with statistical significance, and that we would pause the Reliance II and Relight Phase 3 studies of esmethadone.
Following this 2024 REL-1017 setback, which we believe mostly likely resulted from an overwhelming placebo response a trend that has become more common than exceptional in central nervous system (CNS) clinical trials the program has been paused pending a comprehensive data review, after which we will make a decision regarding the future of this program.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →